CLAIMS

1. The use of a class I histone deacetylase activity inhibitor in the manufacture of a medicament for inhibiting covalently closed circular DNA (cccDNA) transcription of hepatitis B virus.

2. The use according to claim 1, wherein said histone deacetylase activity inhibitor is selected from the group consisting of Trichostatin A, suberoyl bis hydroxamic acid, 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl] benzamide, and Apicidin, or a stereoisomer or pharmaceutically acceptable salt thereof.

3. The use according to claim 1, wherein said histone deacetylase activity inhibitor is Apicidin, or a stereoisomer or pharmaceutically acceptable salt thereof.

4. The use according to claim 1, further wherein the medicament further comprises a therapeutically effective amount of an additional anti hepatitis B infection agent.

5. The use of a class I histone deacetylase activity inhibitor in the manufacture of a medicament for treating hepatitis B.

6. The use according to claim 5, wherein said histone deacetylase activity inhibitor is selected from the group consisting of Trichostatin A, suberoyl bis hydroxamic acid, 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl] benzamide, and Apicidin, or a stereoisomer or pharmaceutically acceptable salt thereof.

7. The use according to claim 5, wherein said histone deacetylase activity inhibitor is Apicidin, or a stereoisomer or pharmaceutically acceptable salt thereof.

8. The use according to claim 5, further wherein the medicament further comprises a therapeutically effective amount of an additional anti hepatitis B infection agent.

9. The use of a class I histone deacetylase activity inhibitor in the manufacture of a medicament for repressing hepatitis B virus covalently closed circular DNA.

10. The use according to claim 9, wherein said histone deacetylase activity inhibitor is selected from the group consisting of Trichostatin A, suberoyl bis hydroxamic acid, 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl] benzamide, and Apicidin, or a stereoisomer or pharmaceutically acceptable salt thereof.

11. The use according to claim 9, wherein said histone deacetylase activity inhibitor is Apicidin, or a stereoisomer or pharmaceutically acceptable salt thereof.

12. The use according to claim 9, further wherein the medicament further comprises a therapeutically effective amount of an additional anti hepatitis B infection agent.